强生医疗:人工智能加速医疗创新

2019-05-20 不详 美通社

5月18日,强生医疗心血管和专业解决方案事业部总经理王金鹤应邀出席“2019年上海科技节 -- 预见未来·人工智能医疗专场”活动,就医疗与创新发表主旨演讲,介绍强生医疗投资于创新,加速人工智能引领医疗创新的愿景、战略和举措。在嘉宾论坛环节,王金鹤与来自沪上知名院校和医疗机构的专家们一起,共同探讨人工智能在医疗等广泛领域的应用和发展方向,向公众描绘未来人工智能支持医疗发展的蓝图,并回答了现场观众的提

5月18日,强生医疗血管和专业解决方案事业部总经理王金鹤应邀出席“2019年上海科技节 -- 预见未来·人工智能医疗专场”活动,就医疗与创新发表主旨演讲,介绍强生医疗投资于创新,加速人工智能引领医疗创新的愿景、战略和举措。在嘉宾论坛环节,王金鹤与来自沪上知名院校和医疗机构的专家们一起,共同探讨人工智能在医疗等广泛领域的应用和发展方向,向公众描绘未来人工智能支持医疗发展的蓝图,并回答了现场观众的提问。

血管和专业解决方案事业部总经理王金鹤做主旨演讲" align="middle" id="prnejpgca86left" alt="强生医疗心血管和专业解决方案事业部总经理王金鹤做主旨演讲" src="https://photos.prnasia.com/prnvar/20190520/2471849-1-a" border="0" imagelabel="General">
强生医疗心血管和专业解决方案事业部总经理王金鹤做主旨演讲

5月18日,强生医疗心血管和专业解决方案事业部总经理王金鹤应邀出席“2019年上海科技节 -- 预见未来·人工智能医疗专场”活动,就医疗与创新发表主旨演讲,介绍强生医疗投资于创新,加速人工智能引领医疗创新的愿景、战略和举措。

王金鹤介绍到,强生是全球具综合性、业务分布范围广的领先医疗健康企业,1985年进入中国市场以来,不断开拓创新,在消费品、制药和医疗器材三大业务领域取得长足发展,服务中国病患和消费者健康需求。王金鹤进一步介绍了强生医疗在中国的业务发展并表示,当前,随着科技进步和人工智能等前沿技术的新发展,在人工智能、大数据、云计算等领域的多种先进技术手段必将对现有医疗技术带来革新性的改变,为包括强生等企业带来更多创新医疗健康解决方案,改善人类健康福祉。

当前,强生进一步加大在人工智能领域战略布局和医疗创新投资,比如与业内伙伴携手合作,研究可穿戴设备对房颤早期识别的影响,改善诊断和治疗效果;研究创造一种更为安全有效的操作系统,和更加聪明的辅助手术机器人,帮助外科医生对手术的控制更精准,也便于术后患者恢复。

创新根植于强生的发展历史。强生在中国成功实现“端到端”研发模式,通过实现从早期研发到临床应用,致力于加速中国创新产品的研发,促进中国创新型经济发展,与医疗领域创新生态系统各方加强合作,共同解决当今许多紧迫的人类健康和公共卫生挑战。

强生医疗积极支持中国医疗生态系统建设,支持“健康中国”发展。2018年12月,中国首台全程可视暨磁电双定位心脏手术在海南博鳌超级医院成功完成,这也是强生医疗研发的全程三维可视、磁电双定位电生理手术在中国医院的首次应用,通过海南博鳌“国际医疗旅游先行区”所享有的“国九条”绿色通道引入中国,为患者带来与国际同步的前沿心脏手术治疗手段。

2019年3月,强生医疗与海南博鳌超级医院宣布共同成立“强生先进技术海南博鳌教育中心”,作为尖端医疗技术人才孵化基地,该中心致力于引入国际前沿医疗技术,搭建系统化、可持续发展的培训体系与学术交流平台,培养一批掌握临床急需先进医疗技术的中国医疗讲师团队和临床专业人才,为患者提供更安全、精准的医疗解决方案。

“创新是医疗发展的核心动力。强生医疗致力于不断创新突破,加速推动前沿科技成果转化,积极促进国外先进技术在国内的推广,使医生和患者可以尽早享受到先进医疗科技带来的安全及便利。”王金鹤表示,“未来,强生将继续加大创新投入,在人工智能、前沿医疗技术等领域加强研发创新。强生也将继续以开放的姿态,与社会各方共同携手,打造健康创新生态系统,推动行业创新,助力建设健康中国,共同迈进健康未来。”

王金鹤与来自沪上知名院校和医疗机构的专家们共同探讨医疗科技发展
王金鹤与来自沪上知名院校和医疗机构的专家们共同探讨医疗科技发展

上海科技节创办于1991年,是上海规模最大的品牌科技活动之一,帮助公众近距离了解最新科技发展、体验科学魅力、提升科学素质。2019年科技节主题为“万众创新 -- 向具有全球影响力的科技创新中心进军”。主要活动包括开幕式、赛事活动、论坛沙龙、视听板块和青少年体验等,传播科学知识,弘扬科学精神,营造爱科学、爱创新的良好社会氛围,打造公众科技嘉年华。

关于强生

在强生,我们坚信健康是活力人生、繁荣社区和不断进步的基础。正因如此,130 多年来,我们始终致力于推进健康事业,让人们在每个年龄段和每个人生阶段都保持健康。今天,作为一家全球业务分布广泛、综合性的跨国医疗健康企业,我们致力于用我们的广泛影响力去促进人类健康、建设更美好社会。我们努力提高医药可及性和可负担性,创造更健康的社区,让世界各地的人都能拥有健康身心,享受健康环境。我们融合关爱、科学与智慧,为人类健康事业的发展带来意义深远的改变。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650978, encodeId=5ac416509e815, content=<a href='/topic/show?id=9abd501e922' target=_blank style='color:#2F92EE;'>#强生医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50179, encryptionId=9abd501e922, topicName=强生医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4d124112960, createdName=mhm297, createdTime=Sat Sep 21 01:45:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741162, encodeId=2aa01e4116224, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Aug 12 01:45:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271696, encodeId=0a1c12e1696df, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285738, encodeId=4bd01285e38d8, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650978, encodeId=5ac416509e815, content=<a href='/topic/show?id=9abd501e922' target=_blank style='color:#2F92EE;'>#强生医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50179, encryptionId=9abd501e922, topicName=强生医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4d124112960, createdName=mhm297, createdTime=Sat Sep 21 01:45:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741162, encodeId=2aa01e4116224, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Aug 12 01:45:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271696, encodeId=0a1c12e1696df, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285738, encodeId=4bd01285e38d8, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650978, encodeId=5ac416509e815, content=<a href='/topic/show?id=9abd501e922' target=_blank style='color:#2F92EE;'>#强生医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50179, encryptionId=9abd501e922, topicName=强生医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4d124112960, createdName=mhm297, createdTime=Sat Sep 21 01:45:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741162, encodeId=2aa01e4116224, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Aug 12 01:45:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271696, encodeId=0a1c12e1696df, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285738, encodeId=4bd01285e38d8, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1650978, encodeId=5ac416509e815, content=<a href='/topic/show?id=9abd501e922' target=_blank style='color:#2F92EE;'>#强生医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50179, encryptionId=9abd501e922, topicName=强生医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4d124112960, createdName=mhm297, createdTime=Sat Sep 21 01:45:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741162, encodeId=2aa01e4116224, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Aug 12 01:45:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271696, encodeId=0a1c12e1696df, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285738, encodeId=4bd01285e38d8, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 22 13:45:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]